This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CS1 chimeric antigen receptor (CAR) T-cell program
Description: CS1 CAR T-cell program is related to CS1, an antigen that is over-expressed inmultiple myeloma cells.
Cellectis and Ohio State University
In January 2015, Cellectis entered into an exclusive license agreement with The Ohio State University, through the Ohio State Innovation Foundation, to develop and commercialize chimeric antigen receptor (CAR) technology targeting multiple myeloma cells.
Cellectis and MD Anderson
In September 2015, Cellectis and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors. The alliance will build on MD Andersons translational and preclinical and clinical teams in leukemia and myeloma, coupled with Cellectis allogeneic CAR T-cell therapy approach and manufacturing capabilities, to pursue the development of Cellectis candidate products UCARTCS1, UCART22, UCART38 in T-cell ALL and UCART123 in a rare non curable disease BPDCN.
Partners: University of Texas MD Anderson Cancer Center
Additional information available to subscribers only: